Literature DB >> 28990401

Reactive Oxygen Species and Their Implications on CD4+ T Cells in Type 1 Diabetes.

Dana M Previte1, Jon D Piganelli1.   

Abstract

SIGNIFICANCE: Previous work has indicated that type 1 diabetes (T1D) pathology is highly driven by reactive oxygen species (ROS). One way in which ROS shape the autoimmune response demonstrated in T1D is by promoting CD4+ T cell activation and differentiation. As CD4+ T cells are a significant contributor to pancreatic β cell destruction in T1D, understanding how ROS impact their development, activation, and differentiation is critical. Recent Advances: CD4+ T cells themselves generate ROS via nicotinamide adenine dinucleotide phosphate (NADPH) oxidase expression and electron transport chain activity. Moreover, T cells can also be exposed to exogenous ROS generated by other immune cells (e.g., macrophages and dendritic cells) and β cells. Genetically modified animals and ROS inhibitors have demonstrated that ROS blockade during activation results in CD4+ T cell hyporesponsiveness and reduced diabetes incidence. Critical Issues and Future Directions: Although the majority of studies with regard to T1D and CD4+ T cells have been done to examine the influence of redox on CD4+ T cell activation, this is not the only circumstance in which a T cell can be impacted by redox. ROS and redox have also been shown to play roles in CD4+ T cell-related tolerogenic mechanisms, including thymic selection and regulatory T cell-mediated suppression. However, the effect of these mechanisms with respect to T1D pathogenesis remains elusive. Therefore, pursuing these avenues may provide valuable insight into the global role of ROS and redox in autoreactive CD4+ T cell formation and function.

Entities:  

Keywords:  CD4+ T cells; ROS; regulatory T cells; type 1 diabetes

Mesh:

Substances:

Year:  2017        PMID: 28990401     DOI: 10.1089/ars.2017.7357

Source DB:  PubMed          Journal:  Antioxid Redox Signal        ISSN: 1523-0864            Impact factor:   8.401


  6 in total

1.  MTH1 as a target to alleviate T cell driven diseases by selective suppression of activated T cells.

Authors:  Stella Karsten; Roland Fiskesund; Xing-Mei Zhang; Petra Marttila; Kumar Sanjiv; Therese Pham; Azita Rasti; Lars Bräutigam; Ingrid Almlöf; Maritha Marcusson-Ståhl; Carolina Sandman; Björn Platzack; Robert A Harris; Christina Kalderén; Karin Cederbrant; Thomas Helleday; Ulrika Warpman Berglund
Journal:  Cell Death Differ       Date:  2022-01       Impact factor: 15.828

Review 2.  Oxidative Stress in Cancer Immunotherapy: Molecular Mechanisms and Potential Applications.

Authors:  Ruolan Liu; Liyuan Peng; Li Zhou; Zhao Huang; Chengwei Zhou; Canhua Huang
Journal:  Antioxidants (Basel)       Date:  2022-04-27

3.  Melatonin, an endogenous hormone, modulates Th17 cells via the reactive-oxygen species/TXNIP/HIF-1α axis to alleviate autoimmune uveitis.

Authors:  Jun Huang; Zhuang Li; Yunwei Hu; Zuoyi Li; Yanyan Xie; Haixiang Huang; Qian Chen; Guanyu Chen; Wenjie Zhu; Yuxi Chen; Wenru Su; Xiaoqing Chen; Dan Liang
Journal:  J Neuroinflammation       Date:  2022-05-27       Impact factor: 9.587

Review 4.  Coordinated regulation of immune contexture: crosstalk between STAT3 and immune cells during breast cancer progression.

Authors:  Jing Jin; Yi Li; Qijie Zhao; Yue Chen; Shaozhi Fu; JingBo Wu
Journal:  Cell Commun Signal       Date:  2021-05-06       Impact factor: 5.712

5.  Hyperuricemia Predisposes to the Onset of Diabetes via Promoting Pancreatic β-Cell Death in Uricase-Deficient Male Mice.

Authors:  Jie Lu; Yuwei He; Lingling Cui; Xiaoming Xing; Zhen Liu; Xinde Li; Hui Zhang; Hailong Li; Wenyan Sun; Aichang Ji; Yao Wang; Huiyong Yin; Changgui Li
Journal:  Diabetes       Date:  2020-04-20       Impact factor: 9.461

Review 6.  New Developments in T Cell Immunometabolism and Therapeutic Implications for Type 1 Diabetes.

Authors:  Mengdi Zhang; Yanyan Zhou; Zhiguo Xie; Shuoming Luo; Zhiguang Zhou; Jiaqi Huang; Bin Zhao
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-10       Impact factor: 6.055

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.